Cemiplimab (PDCD1/PD1/CD279) - Biosimilar Research Grade
Kwaliteit
ISO Gecertificeerd
Levering
24-48 uur
Technische Specificaties
Cemiplimab is fully human PD-1 antibody. The first indication for marketing application is metastatic / local advanced squamous cell carcinoma (Cutaneous Squamous Cell Carcinoma, CSCC) . It is an intravenous immunotherapy targeting the PD-1 pathway that can help the immune system fight cancer cells.
Homo sapiens / PDCD1/PD1/CD279 [Homo sapiens]
• Recombinant Monoclonal
Unconjugated
Primary Antibodies, Biosimilars
CHO cells
Cancer, Immunology
>95%
Batch dependent
PBS buffer pH7.5
None
Blue Ice
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚ C for 1-2 weeks. Store at -20 ˚ C for 12 months. Store at -80 ˚ C for long term storage.
IgG4-kappa
Homo sapiens
REGN-2810, SAR-439684, cemiplimab-rwlc
Beschrijving
Cemiplimab (PDCD1/PD1/CD279) - Biosimilar Research Grade Beschikbaar in 0.1 mg. Bestel eenvoudig online met snelle levering.
Specificaties
Recent bekeken producten
Arachis hypogaea Lectin (PNA) - Biotinylated
21510020-1
5mg
1,4- Dioxane Pure
1041330 500
500 mL
Benzonase ELISA Kit
EG23601S
96 Tests
Not I Restriction Enzyme
B2016623
500 Units
K562-HLA-G0101 Overexpressing Cell Line
RG-1214
5x 10^6
Yeast Poly (A) Polymerase
RNT-006-S
30000 Units
Arachis hypogaea lectin (PNA)
05-0116-10mg
10 mg
Anti-APOE2 mouse monoclonal antibody
TD-AB0132
100 µg